Kit formulation of active pharmaceutical ingredient d,l-HMPAO as a brain perfusion diagnostic system

Mohammadreza Davarpanah, Hossein Abbasi, Mehdi Nabati*, Hamideh Sabahnoo, Vida Bodaghi-Namileh, Mohammad Mazidi, Hossein Movahhed-Tazehkand, Hossein Mohammadnejad-Mehrabani

Synthesis and Molecular Simulation Laboratory, Chemistry Department, Pars Isotope Company, P.O. Box: 1437663181, Tehran, Iran

ARTICLE INFO

Article history:
Submitted: 2019-09-26
Revised: 2019-10-19
Accepted: 2019-11-01
Available online: 2019-11-08
Manuscript ID: PCBR-1909-1062

KEYWORDS

Exametazime
HMPAO
Kit Formulation
Nuclear medicine
Radiopharmaceutical
Technetium-99m radionuclide

ABSTRACT

The purpose of this research study is to prepare exametazime (d,l-HMPAO) kit for labeling with 99m-technetium radionuclide as a brain perfusion diagnostic system. Firstly, the active pharmaceutical ingredient d,l-HMPAO was prepared in two steps with the purity of 99.29 %. Its molecular structure was characterized using elemental analysis, Fourier-transform infrared spectroscopy (FT-IR), and nuclear magnetic resonance (NMR) technique. In second step, the d,l-HMPAO kit was prepared using six different formulations and labeled by technetium-99m radionuclide. The high radiochemical yield was attributed to the high amount of SnCl₂ and adding phosphate buffer. The animal studies were conducted on the three-month old male Wistar rats. The results of the biodistribution studies revealed that, the mean activity in brain of all rats was above 1% ID/g. This showed the high isomerism purity of the synthesized compound (d,l-HMPAO) and optimization of the suggested formulations.
1. Introduction

Exametazime which is mainly known by its chemical name hexamethy[propyleneamine-oxime or HMPAO has been used as a chelating agent to bind with technetium-99m [1]. Technetium-99m (99mTc) is an isotope of technetium-99 and a gamma-emitter agent utilized in various fields of diagnostic medicine. In addition, based on its favorable qualities, 99mTc is one of the most investigated radioisotopes in nuclear research areas [2]. The HMPAO ligand comprises of two diastereomeric isoforms are including d,l-HMPAO and meso-HMPAO [3]. 99mTc-d,l-HMPAO is a well-established radiotracer in cerebral imaging and leukocytes labeling for detection of several infectious and inflammatory diseases [4, 5]. 99mTc-d,l-HMPAO is the first 99mTc-labeled tracer used for evaluating the regional cerebral blood (rCBF) [6-10]. Regional cerebral blood flow represents the amount of blow flow to a specific region of the brain in a predetermined time [11]. Considering the fact that various pathological processes in the brain originate from alterations in cerebral blood perfusion, the diagnostic capabilities of 99mTc-d,l-HMPAO is of particular importance in early detection of neurocognitive disorders such as schizophrenia [12], major depressive disorder [13], epilepsy [14], migraine [15], meningioma [16], and Alzheimer's [17]. 99mTc-d,l-HMPAO SPECT (single-photon emission computed tomography) is considered to be one of the most reliable scintigraphic studies and imaging methods in early diagnosis of dementia [18]. Due to its lipophilic nature, 99mTc-d,l-HMPAO readily permeates through blood-brain barrier (BBB) and converts into hydrophilic species incapable of back-diffusion thus guaranteeing entrapment of the agent in brain cells. Within one minute after the injection of 99mTc-d,l-HMPAO, a maximum of 3.5-7.0% of the injected dose is up-taken into the brain although up to 15% of the activity is lost after about only 2 min [19-21]. The objective of the current study was to introduce a novel route for the synthesis of the active pharmaceutical ingredient (d,l-HMPAO) for the preparation of 99mTc-d,l-HMPAO radiopharmaceutical. In addition, different kit formulations were suggested, with minor alterations in previously investigated formulations, and further analyzed to reach two optimum formulations with the best observed results. Due to the inherent instability of 99mTc-d,l-HMPAO and its spontaneously degradation into hydrophilic agents, quality control measures were carried out in a span of 5 to 30 min after labeling procedure. Furthermore, to gain a better insight into this radiopharmaceutical’s behavior and function in vivo, animal studies were conducted and regional brain perfusion was investigated in Wistar rats. Moreover, the amounts of liver and kidney uptake were measured as indicators of metabolism and elimination, respectively.

2. Experimental

2.1. Materials and Methods

2,3-Butanedione monoxime, KHPO₄, KH₂PO₄, tin (II)-chloride dehydrate, tin (II) fluoride and ethyl acetate was purchased from Sigma-Aldrich (St. Louis, MO, USA). The 99mTcO₄Na was eluted from a 99Mo/99mTc radionuclide generator (Pars Isotope, Tehran, Iran). Ethanol, 2,2-dimethyl-1,3-propanediamine, para-toluene sulfonic acid monohydrate, benzene, sodium hydroxide, sodium chloride, sodium borohydride, acetic acid, acetonitrile and methyl ethyl ketone was obtained from Merck (Darmstadt, Germany). Distribution of the radioactivity on the chromatography papers were quantified using a Lablogic mini scan TLC scanner (Sheffield, UK) and analyzed with Lura image analysis software.

2.2. Optimized synthesis and characterization of d,l-HMPAO

Scheme 1 shows the molecular structure of active pharmaceutical ingredient d,l-HMPAO. In our previous study, we discussed the reactivity and stability of the d,l-HMPAO and its complex with 99m-tecnieteum.
In this work, we synthesized this medicinal compound in two steps. Firstly, 73 g of 2,3-Butanedione monoxime, 0.2 g of para-toluene sulfonic acid monohydrate and 750 mL of benzene were added to a 2 L round-bottomed flask equipped with a Dean–Stark trap. The reaction mixture was heated (85 °C) and normally stirred for 2 h. The reflux process was continued until the solid was completely dissolved. Then, 60 g of 2,2-dimethyl-1,3-propanediamine was dissolved in 100 mL of benzene. This solution was added dropwise into the flask. The reaction mixture was refluxed for 20 h. Then, the yellow colored solution was stirred for 24 h at 4 °C. The white solid formed was collected by Buckner filtration, washed with cold acetonitrile four times (each time with 250 mL of solvent). The white solid compound was dried under the vacuum over calcium chloride. 96.8 g of this compound was obtained. In second step, 96 g of the white solid compound and 930 mL of absolute ethanol were added in a 2 L round-bottomed flask and stirred in an ice bath. Then, 20.4 g of sodium borohydride (NaBH₄) was gradually added to the reaction mixture over a period of 2 h. After adding sodium borohydride, the reaction mixture was stirred for 3 h. After this time, 290 mL of deionized water was added into the flask. The reaction mixture was stirred for 1 hour at 0–5 °C. Then, 92.52 mL of acetic acid was added dropwise to the flask. The reaction mixture was then warmed to room temperature and stirred overnight. The next day, ethanol was removed under vacuum. Then, the pH of the residual slurry was adjusted to 11 and was kept overnight at 4 °C to complete the precipitation. After 24 h, the white precipitation was collected by Buckner filtration and washed with 4 L of cold deionized water and dried under vacuum over calcium chloride. This white solid compound is a mixture of d,l-HMPAO and meso-HMPAO. We isolated the d,l-HMPAO isomer from the meso-HMPAO isomer using acetonitrile and ethyl acetate solvents. The isomers mixture was treated with 400 mL hot acetonitrile under severely magnetic stirring. Then, it was filtered and the solute was kept in refrigerator for three days. The white precipitated compound was filtered and dissolved in 400 mL of hot ethyl acetate. The solution was filtered and the solute kept in refrigerator for three days. The white compound was collected and dissolved in 400 mL of acetonitrile again. The solution was filtered and the solute kept for another three days in refrigerator. Finally, the white product was collected and died under vacuum over calcium chloride. The yield of the final compound was 5.1 g.

Scheme 1. Molecular structure of d,l-HMPAO

Evaluation of d,l-HMPAO Kit Formulation

As seen in Table 1, five alternative formulations A–E were prepared by changing the affected parameters in radiochemical yield including, the amounts of SnCl₂, percentage of solvent ethanol, pH and stabilizer agents (such as phosphate buffer). For radiolabeling, to any formulations, we added a sodium pertechnetate (Na₉⁹mTcO₄⁻) containing 3-4 mL of 40-50 mCi of ⁹⁹mTcO₄⁻. The reaction was incubated at room temperature for 30 min. Then the radiochemical yield was determined using the ITLC-SG and Whatman ET31 chromatography papers in different mobile phases such as normal saline, mixture of (saline and acetonitrile) and Methyl Ethyl Ketone (MEK). In TLC, when normal saline was used as mobile phase, free ⁹⁹mTcO₄⁻ and ⁹⁹mTc-HMPAO-secondary migrate to the solvent front (Rf=1.0), while ⁹⁹mTc-HMPAO lipophilic and colloid remain at the application point (Rf=0.0). However, for MEK system the colloids and secondary remain near the point of spotting (Rf=0.0–0.3) and ⁹⁹mTc-HMPAO lipophilic and free ⁹⁹mTcO₄⁻ moved towards the solvent front. In mixture of saline and acetonitrile (1:1) only colloid remains at the
application point and other radiolabeled complex moved towards. Radiolabeling yield of the kits was determined using TLC at 30 min.

In the same condition of kit formulations, high radiochemical yield was accepted by adjusting pH in range 9-9.30 (compare to formulation A and B). Optimum formulation was determined by adding less percentage of solvent ethanol (formulation C). The amount of ethanol present would make it unstable for radiolabeling. However, high radiochemical yield was accepted by using high amount of SnCl₂ and adding phosphate buffer (formulation D).

**Animal Studies**

Three-month old male Wistar rats weighing 150-200 g were acquired from the Animal House, Pars Isotope Company, Tehran, Iran. The animals were housed in standard laboratory conditions (20± 5°C and 14h dark-10h light cycle) and provided with water and standard diet. The animals were allocated into 2 equal groups of 6 rats, each receiving 100 mCi of ⁹⁹ᵐ-Tc-l,d-HMPAO injections through the animal’s tail vein. One hour after administration all rats were anesthetized by xylidine and further euthanized. Afterwards, the rats’ organs were immediately extracted and weighed. To measure the tracer’s uptake by different organs, a standard gamma counter was utilized and related results were reported by percentage injected dose per gram (%ID/g) of tissue and percentage injected dose per organ (%ID/organ), 1 and 10 min after injection. The ⁹⁹ᵐ-Tc-l,d-HMPAO 1 and 10 min biodistribution results are presented in Table 1. As presented in Table 1, the mean activity in brain of all rats reached above 1% ID/g, indicating complete purity of synthesized isomer and optimization of the suggested formulations. Moreover, the high mean counts in liver suggests hepatic metabolism of the investigated agent.

### 3. Results and Discussion

#### 3.1. Characterization of d,l-HMPAO

The purity of the d,l-HMPAO was gained by HPLC using a μ-Porasil normal phase column, with a UV 210 nm detector, with methanol:0.4M NH₄OH (95:5) as the mobile phase at a flow rate of 1 mL/min. In this system, there is a difference of 1 min between the retention times of the d,l-HMPAO and the meso-HMPAO. The HPLC analysis showed % 99.29 for this isomer (d,l-HMPAO). Melting point of d,l-HMPAO isomer: 133 °C.

| Table 1. Condition of optimum formulation of ⁹⁹ᵐTc-HMPAO complex |
|-------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Formulation | HMPAO (mg) | SnCl₂ (µg) | NaCl (mg) | EtOH (%(V/V)) | Buffer | pH | % (Labeling Yield) 30 min |
|---|---|---|---|---|---|---|
| A | 0.5 | 8 | 4.5 | 10 | - | 9-9.5 | 80 |
| B | 0.5 | 8 | 4.5 | 10 | - | 7.5-8 | 30 |
| C | 0.5 | 8 | 4.5 | 4 | - | 9-9.5 | 97 |
| D | 0.5 | 13.5 | 4.5 | 4 | phosphate | 9-9.5 | 97 |
| E | 0.5 | 7.6 | 4.5 | 4 | - | 9-9.5 | 92 |
| F | 0.5 | 6.3 (SnF₂) | 4.5 | 4 | - | 9-9.5 | 92 |
Table 2. Biodistribution of $^{99m}$Tc-d,l-HMPAO in male Wistar rats

<table>
<thead>
<tr>
<th>Biodistribution</th>
<th>Time (min)</th>
<th>Brain</th>
<th>Blood</th>
<th>Liver</th>
<th>Kidney</th>
<th>Stomach</th>
<th>Intestine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Count</td>
<td>1</td>
<td>1.74±0.06</td>
<td>8.46±2.79</td>
<td>20.32±1.91</td>
<td>3.90±0.11</td>
<td>1.92±0.32</td>
<td>15.87±0.79</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>0.40±0.01</td>
<td>9.13±0.96</td>
<td>22.66±1.58</td>
<td>3.15±0.12</td>
<td>0.89±0.55</td>
<td>16.85±1.17</td>
</tr>
</tbody>
</table>

Elemental analysis: C (% 57.82), H (% 10.11) and N (% 20.96).

FT-IR (KBr, $\nu$ cm$^{-1}$): 1488, 1533, 1654, 1705, 1863, 2919, 2931, 2956, 2987, 2992, 3023, 3030, 3036, 3088, 3111, 3129, 3150-3450.

$^1$H-NMR (CD3OD, 500 MHz, $\delta$ ppm): 0.99 (s, 6H, gem-CH$_3$), 1.17 (d, 6H, NH-CH$_2$CH$_3$), 2.98 (s, 6H, HON=C-CH$_3$), 2.41 (4H, CH$_2$NH) and 2.86 (q, 2H, NHCH-CH$_3$).

$^{13}$C-NMR (proton decoupled) (CD3OD, 500 MHz, $\delta$ ppm): 13.2, 15.5, 23.5, 33.6, 43.2, 59.7 and 164.6.

3.2. Results of the d,l-HMPAO Kit Formulations

Previously a reported formulation kit of HMPAO was as a formulation E (Ceretec$^{\text{TM}}$ kit) but results revealed a decrease in the $[^{99m}\text{Tc}]$Tc-D,l-HMPAO radiochemical yield (increasing $^{99m}$Tc-HMPAO-secondary), 30 min from kit reconstitution. In our survey, a lipophilic compound is decomposed due to molecular structure instability, high radiation doses, SnCl$_2$ excess and high pH. For above reasons, we explored effect of pH, buffer, SnCl$_2$ amount and solvent on the stability of $[^{99m}\text{Tc}]$ Tc-D, L-HMPAO. In the same condition of kit formulations, high radiochemical yield was accepted by adjusting pH between 9 and 9.30 (compare to formulation A and B). Optimum formulation was determined by adding less percentage of solvent Ethanol (formulation C). The amount of EtOH present would make it unstable for radiolabeling. However, high radiochemical yield was accepted by using high amount of SnCl$_2$ and adding phosphate buffer (formulation D). As the rate of decomposition of the lipophilic complex increased at the presence of excess stannous Sn (II) ion, the amount of stannous chloride in the kit became very low. For using high amount of stannous chloride (for strong labeling), we added pH-adjusting agent and free radical scavenger (phosphate buffer) to oxidize excess Sn (II) ion remaining after labeling. At the formulation F, we used stannous fluoride instead of stannous chloride as reducing agent. There were two reasons for this: different coordination chemistry with N- or O-donor ligands and different reaction in ethanol with those ligands. Unexpectedly, results (comparison between formulation E and F) revealed that, radiochemical yield was same at different formulations.

4. Conclusions

This work aimed at preparation of d,l-HMPAO kit for labeling with 99m-technetium radionuclide as a brain perfusion diagnostic system. Synthesis and preparation of the active compound d,l-HMPAO (exametazime) was carried out at two steps. The prepared active pharmaceutical ingredient was purified using solvent-antisolvent purification method and characterized by spectroscopy techniques. The purity of the synthesized active substance was above 99 percent. In second step, the d,l-HMPAO kit was prepared using different formulations and labeled by 99m-technetium radionuclide. The formulation containing high amount of SnCl$_2$ and adding phosphate buffer showed the high radiochemical yield. It
was found that, the mean activity in brain of all rats was above 1% ID/g. This indicated complete purity of the synthesized isomer (d,L-HMPAO) and optimization of the suggested formulations.

Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.

References


Acknowledgments
The authors are grateful to Dr. Fariba Joharidaha, Dr. Nasim Vahidifar and Mr. Farzad Farajbakhsh for providing in valuable support in this research study.


